LOCAL FIELD POTENTIALS AND NEURAL ACTIVITY IN MOTOR NETWORKS IN LEVODOPA-INDUCED DYKINESIA IN A MODEL OF PARKINSON'S DISEASE

被引:0
|
作者
Brazhnik, E. S. [1 ]
Mysin, I. E. [1 ]
Novikov, N. I. [1 ]
机构
[1] Inst Theoret & Expt Biophys, Fed State Budgetary Educ Inst, Pushchino, Russia
关键词
Parkinson's disease; basal ganglia; beta- and gamma-oscillations; bradykinesia; coherence; dyskinesia; MOVEMENT-RELATED CHANGES; BASAL GANGLIA OUTPUT; OSCILLATORY ACTIVITY; SUBTHALAMIC NUCLEUS; GAMMA-ACTIVITY; SYNCHRONIZATION; DYSKINESIA;
D O I
10.31857/S0044467724050058
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Levodopa, a metabolic precursor of dopamine (DA), is used to treat movement disorders in Parkinson's disease (PD). Long-term use of levodopa causes a serious side effect known as levodopa-induced dyskinesia (LID). With the development of LID, high-frequency gamma oscillations (80-120 Hz) are reported in recordings of local field potentials (LFPs) from the motor cortex (MCx) in rats with experimental PD and in patients with Parkinson's disease. The mechanisms underlying the occurrence of these oscillations and their connection with LID are not entirely clear. The study of activity in divisions of the motor network can provide valuable information about the mechanisms of development of pathological gamma-oscillations and LID. Rats with experimental PD were treated with levodopa for 7 days. Local field potentials and neural activity were recorded from electrodes implanted in the motor cortex, ventromedial nucleus of the thalamus (Vm), and substantia nigra pars reticularis (SNpr). Dyskinesia was assessed using a standard abnormal involuntary movement scale. Administration of levodopa significantly reduced the power of beta-oscillations (30-36 Hz) in all 3 parts of the motor neural network associated with bradykinesia in PD and caused the appearance in Vm and MCx coherent LFP oscillations in the high gamma-frequency range. Their coherence increased during priming between days 1 and 7. This activity was strongly associated with the occurrence of dyskinesia. In LID, an increase in the frequency of neuronal activity in Vm and MCx was accompanied by increased synchronization of neuronal activity with cortical gamma-oscillations in VM (68%) and MCx (25%). In contrast to Vm and MCx, SNpr did not exhibit gamma-range oscillatory activity during LID, and its neural activity was not synchronized with LFPs in Vm or MCx. It is significant that during the LID period the frequency of SNpr spike activity in most recordings (76%) decreased significantly and was approximately three times lower than the initial one (before the administration of levodopa). Administration of the antidyskinetic drug, 8-OH-DPAT, restored the initial characteristics of LFPs (30-36 Hz oscillation), neuronal activity, and bradykinesia. Thus, repeated administration of levodopa leads to a decrease of the inhibitory control in motor neural networks due to a significant reduction in activity of SNpr. Obviously, Vm and SNpr can be considered as the most important components of the motor neural network, making the main contribution to the occurrence of high-frequency gamma oscillations and LID.
引用
收藏
页数:126
相关论文
共 50 条
  • [21] Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson's disease
    Phillips, Joseph R.
    Eissa, Abeer M.
    Hewedi, Doaa H.
    Jahanshahi, Marjan
    El-Gamal, Mohamed
    Keri, Szabolcs
    Moustafa, Ahmed A.
    REVIEWS IN THE NEUROSCIENCES, 2016, 27 (07) : 729 - 738
  • [22] Dorsolateral striatal neuronal activity in a rat model of Parkinson's disease with levodopa-induced dyskinesias
    Jin, X.
    Milakara, D.
    Schwabe, K.
    Krauss, J.
    Alam, M.
    MOVEMENT DISORDERS, 2019, 34 : S725 - S725
  • [23] Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson’s disease
    Domiziana Rinaldi
    Lanfranco De Carolis
    Francesco Ceriello
    Edoardo Bianchini
    Francesco E. Pontieri
    Neurological Sciences, 2022, 43 : 4571 - 4572
  • [24] Management of levodopa-induced dyskinesias in Parkinson's disease
    Kashihara, Kenichi
    JOURNAL OF NEUROLOGY, 2007, 254 (Suppl 5) : 27 - 31
  • [25] Levodopa-Induced Neurovascular Changes in Parkinson's Disease
    Jourdain, Vincent A.
    Tang, Chris C.
    Dhawan, Vijay
    Eidelberg, David
    ANNALS OF NEUROLOGY, 2015, 78 : S52 - S52
  • [26] Treatment of levodopa-induced dystonia in Parkinson's disease
    Pirtosek, Z
    5TH CONGRESS OF THE EUROPEAN SOCIETY FOR CLINICAL NEUROPHARMACOLOGY, 2000, : 193 - 200
  • [27] "Cueing" for Levodopa-Induced Dyskinesias in Parkinson's Disease
    Schaeffer, Eva
    Linke, Gerd
    Berg, Daniela
    FRONTIERS IN NEUROLOGY, 2016, 7
  • [28] Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson's disease
    Rinaldi, Domiziana
    De Carolis, Lanfranco
    Ceriello, Francesco
    Bianchini, Edoardo
    Pontieri, Francesco E.
    NEUROLOGICAL SCIENCES, 2022, 43 (07) : 4571 - 4572
  • [29] Levodopa-induced ocular dyskinesia in Parkinson's disease
    Groetzsch, H.
    Sztajzel, R.
    Burkhard, P. R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (10) : 1124 - 1128
  • [30] Management of levodopa-induced dyskinesias in Parkinson's disease
    Kenichi Kashihara
    Journal of Neurology, 2007, 254 : 27 - 31